StockData

Gelteq vs Vyome

GELS and HIND side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How GELS and HIND compare

Vyome scores higher on the StockData Score (1 against 0 for Gelteq), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricGELSHIND
Size and price
Market cap–$11.1M
Share price$0.380$1.58
Change, 1 year−64.1%−70.3%
Change, 5 years–−100.0%
Beta (5Y)2.501.56
Employees–18
StockData Score
Total score01 (better)
Valuation score00
Growth score00
Performance score00
Health score01 (better)
Dividend score00
Valuation
P/S–72.4×
Growth
Revenue growth (TTM)–−55.6%
Revenue growth, 5Y average–−51.0%
Profitability
Gross margin30.3%50.4% (better)
Operating margin−3318%−2854% (better)
Net margin–−2456%
FCF margin−3335%–
Return on equity–−149%
Financial health
Interest coverage−2.8× (better)−229.3×
Current ratio0.093.68 (better)
Altman Z-score–−12.31
Piotroski F-score–4
Dividends and buybacks
Buyback yield–−53.1%
Shareholder yield–−53.1%
Ownership
Held by institutions–2.0%
Held by insiders14.0%6.8%
Short interest, % of float–0.28%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.